PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-135566 |   Pharmaceuticals And Medical

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Pharma Contract Manufacturing Organisations (Cmos) for Injectable Drug Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET

7.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Catalant

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Boehringer Ingelheim

16.3 Lonza AG

16.4 Grifols International SA

16.5 AbbVie Inc

16.6 Patheon Inc

16.7 Vetter

16.8 Aenova Group

16.9 Almac Group

16.10 Pharmaceutical Product Development

16.11 CMIC Group

16.12 Nectar Lifesciences

16.13 WuXi AppTec

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type
Blood Factors
Cytokines
Peptide Hormone
Immunoglobulin
Monoclonal Antibodies (mAbs)
Insulin
Other Drug Classes

By Application
Pharma Company
Biotech Company

Companies

Catalant
Boehringer Ingelheim
Lonza AG
Grifols International SA
AbbVie Inc
Patheon Inc
Vetter
Aenova Group
Almac Group
Pharmaceutical Product Development
CMIC Group
Nectar Lifesciences
WuXi AppTec

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.